Back to search
FDAFDA · Food and drugs·Recall number D-324-2013

Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1.

Published May 22, 2013 · Recall initiated: January 31, 2013

Summary

FDA records drug Class I recall D-324-2013, published May 22, 2013 and initiated January 31, 2013. Recalling firm: Gilead Sciences, Inc.; Status: Terminated; Reported quantity: 3,181 vials; Lot: Lot #: B120217A, Exp 05/15 - US Distribution. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Gilead Sciences, Inc.
Distributor
Nationwide in USA, Canada, and UK (Gilead facility in Cork Ireland). Cork facility distributed to Germany/Austria, Italy and Spain.
Lot
Lot #: B120217A, Exp 05/15 - US Distribution
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Vistide (cidofovir) Injection, 375 mg (75 mg/mL), 5 mL single-use vial, Rx only, Manufactured for: Gilead Sciences, Inc., Foster City, CA 94404, UPC 3 61958 01011 5; NDC 61958-0101-1. recalled?

Yes. FDA published recall D-324-2013 on May 22, 2013. Reported hazard: Presence of Particulate Matter: Particulate matter was found in some vials of Vistide (cidofovir injection).

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail